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Abstract
Background: More than 80% of intestinal neoplasia is associated with the adenomatous polyposis coli (APC)
mutation. Doublecortin-like kinase 1 (Dclk1), a kinase protein, is overexpressed in colorectal cancer and specifically
marks tumor stem cells (TSCs) that self-renew and increased the tumor progeny in ApcMin/+ mice. However, the role
of Dclk1 expression and its contribution to regulating pro-survival signaling for tumor progression in Apc mutant
cancer is poorly understood.
Methods: We analyzed DCLK1 and pro-survival signaling gene expression datasets of 329 specimens from TCGA
Colon Adenocarcinoma Cancer Data. The network of DCLK1 and pro-survival signaling was analyzed utilizing the
GeneMANIA database. We examined the expression levels of Dclk1 and other stem cell-associated markers,
pro-survival signaling pathways, cell self-renewal in the isolated intestinal epithelial cells of ApcMin/+mice with
high-grade dysplasia and adenocarcinoma. To determine the functional role of Dclk1 for tumor progression, we
knocked down Dclk1 and determined the pro-survival signaling pathways and stemness. We used siRNA technology to
gene silence pro-survival signaling in colon cancer cells in vitro. We utilized FACS, IHC, western blot, RT-PCR, and
clonogenic (self-renewal) assays.
Results: We found a correlation between DCLK1 and pro-survival signaling expression. The expression of Dclk1 and
stem cell-associated markers Lgr5, Bmi1, and Musashi1 were significantly higher in the intestinal epithelial cells of
ApcMin/+mice than in wild-type controls. Intestinal epithelial cells of ApcMin/+mice showed increased expression of
pro-survival signaling, pluripotency and self-renewal ability. Furthermore, the enteroids formed from the intestinal
Dclk1+ cells of ApcMin/+mice display higher pluripotency and pro-survival signaling. Dclk1 knockdown in ApcMin/+ mice
attenuates intestinal adenomas and adenocarcinoma, and decreases pro-survival signaling and self-renewal. Knocking
down RELA and NOTCH1 pro-survival signaling and DCLK1 in HT29 and DLD1 colon cancer cells in vitro reduced the
tumor cells’ ability to self-renew and survive.
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Conclusion: Our results indicate that Dclk1 is essential in advancing intestinal tumorigenesis. Knocking down Dclk1
decreases tumor stemness and progression and is thus predicted to regulate pro-survival signaling and tumor cell
pluripotency. This study provides a strong rationale to target Dclk1 as a treatment strategy for colorectal cancer.
Keywords: Dclk1, APC mutation, Cancer stem cells, Intestinal epithelial cells, Pro-survival signaling, Self-renewal,
Nanoparticles, Colorectal cancer
Background
APC is a tumor suppressor gene that is mutated in pa-
tients with familial adenomatous polyposis (FAP) and
most sporadic colorectal cancers [1, 2]. The Apc muta-
tion dysregulates the Wnt signaling pathway and triggers
cellular transformation, resulting in the development of
adenomatous polyps [3]. It was suggested that the APC
gene mutation is required, but is not sufficient, for the
development of cancer in the colon. Since tumorigenesis
is considered the result of multiple genetic changes, sev-
eral efforts have made to identify those tumorigenesis-
promoting changes. Several genetic changes, including
activation mutations in Ki-RAS/N-RAS, mutations in the
tumor suppressor TP53, and deletion of a region of
chromosome 18 containing SMAD2, SMAD4, and DCC
have been identified [4]. Despite improvements in our
understanding of this disease, the molecular events
underlying the development and progression of intes-
tinal tumors are still largely unknown and may be a key
to the development of more effective and novel thera-
peutic strategies. Therefore, understanding the APC
gene mutation associated changes for intestinal tumori-
genesis is important.
Similar to humans with germline mutations in APC,
ApcMin/+ mice have a heterozygous mutation in the Apc
gene, predisposing the mice to intestinal and colon
tumor development. These mice start developing intes-
tinal polyps by ~4 weeks of age, with progression to dys-
plasia at 18–21 weeks; adenocarcinoma is also evident at
~26-34 weeks [5–8]. Eight-to-twelve-week-old ApcMin/+
mice are a good model with which to study the patho-
genesis of FAP, while 26-to-34-week-old ApcMin/+ mice
develop intestinal high-grade dysplasia and adenocarcin-
oma, and are a particularly relevant model for studying
tumor progression and developing therapeutic strategies
[6, 7]. ApcMin/+ mice develop high-grade dysplasia and
adenocarcinoma and are a clinically relevant disease
model, since a large number of patients diagnosed with
advanced colon cancer are elderly and have unresectable
or widespread disease [9].
Doublecortin-like kinase 1 (Dclk1) is a microtubule-
associated protein kinase and has been identified as a
tuft cell marker in the small intestine [10]. Dclk1 has
been reported to mark tumor stem cells in the intestine
and pancreas [11–15]. Emerging evidence has confirmed
that the majority of human malignancies are initiated
and maintained by a distinct population of cells that dis-
play stem cell properties and self-renewal ability [16].
More recently, it has been shown that the development
and progression of colon and pancreatic cancer depend
upon Dclk1+ cancer stem cells [11, 13–15]. We reported
that Dclk1 is overexpressed in many cancers, including
colon, pancreas, liver, and esophageal cancer [12, 17–20].
Previous work from others and us supported the idea that
DCLK1 expression is critical for cancer stem cells, cancer
growth, EMT, and metastasis [11, 12, 15, 18, 21–23].
These data provide a basis for Dclk1 as a regulatory factor
for tumor growth and advancement.
Recent studies have indicated that neoplastic cells have
active pro-survival signaling pathways for proliferation,
resistance, self-renewal, and survival [24–26]. Further-
more, progression of cancer, including metastasis and
secondary tumor formation of cancer cells with self-
renewal ability, is often linked to altered expression of
pro-survival signaling pathways [27]. Understanding the
diversity of pro-survival signaling pathways that underlie
cancer formation and progression is essential for devel-
oping a new generation of effective anticancer drugs for
combinatorial therapeutic strategies. The interdependence
between pro-survival signaling and tumor self-renewal
ability with enhanced Dclk1 highlights the collective
mechanism involved in tumor growth and survival. How-
ever, the precise mechanism by which Dclk1 supports
intestinal tumor progression is poorly understood. With
the aid of the ApcMin/+ mouse model, we assessed the con-
tribution of Dclk1 to intestinal tumorigenesis using small
interfering RNAs targeting Dclk1 incorporated into
poly(lactic-co-glycolic acid) nanoparticles (siDclk1-NPs).
We found that Dclk1 is involved in enhancing the pro-
survival signaling pathways and tumor cells’ self-renewal
ability to facilitate intestinal tumor growth and progression.
Methods
TCGA Colon Adenocarcinoma (COAD) Data
The RNA-seq datasets from February 2015 combining
data from 329 patients with colon adenocarcinomas in-
cluded in the Cancer Genome Atlas (TCGA) dataset
were downloaded through the UCSC cancer genome
browser (https://www.xenabrowser.net), as previously
described [28].
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Determination of DCLK1-correlated pro-survival signaling
in APC mutant COAD
APC mutant/APC non-mutant samples and samples
with high/low DCLK1 expression levels were sorted by
R v3.2. Patients whose DCLK1 expression levels was in
the top 25% or bottom 25% were considered DCLK1-
high or DCLK1-low, respectively. The corrplot function
(R package corrplot) was used to confirm the correlation
between the expression levels of DCLK1 and other
genes. A heatmap was produced using the heatmap.2
function (R package gplots) [28].
DCLK1 network with pro-survival signaling utilizing the
GeneMANIA database
Datasets, including physical interactions, pathway, and gen-
etic interactions, were collected from the public domain
GeneMANIA database. The dataset relevant to DCLK1
and the pro-survival signaling network was produced from
the GeneMANIA database (http://www.genemania.org).
Animals
All animal experiments were performed with approval
and authorization from the Institutional Review Board
and the Institutional Animal Care and Use Committee
at the University of Oklahoma Health Sciences Center
(Oklahoma City, Oklahoma). ApcMin/+ mice on the
C57BL/6 J background were obtained from The Jackson
Laboratory and were maintained by breeding ApcMin/+
males to C57BL/6 J females. Mice were genotyped with
a PCR assay to identify carriers of the Min allele of Apc.
Same sex (male) C57BL/6 J ApcMin/+ and Apc+/+ litter-
mates at 30 week of age were used in the present study.
The average life span of ApcMin/+ mice on the C57BL/6 J
background is ∼ 20 weeks, although the mice in our facil-
ity have healthier survival, as observed in several previ-
ous studies [5–8]. ApcMin/+ mice (i.e., >30 weeks of age)
were carefully monitored and sacrificed before becoming
moribund.
Intestinal Epithelial Cell (IEC) Isolation
Small intestines (ileum) were attached to a paddle, were
immersed in Ca2+-free standard Krebs-buffered saline
(in mmol/l: 107 NaCl, 4.5 KCl, 0.2 NaH2PO4, 1.8
Na2HPO4, 10 glucose, and 10 EDTA) at 37 °C for 15–
20 min, and were gassed with 5% CO2, 95% O2. Individ-
ual crypt units were then separated by intermittent
(30 s) vibration into ice-cold phosphate buffered saline
and were collected by centrifugation [18, 29–31]. We
utilized the whole intestinal epithelilal cells.
FACS
Freshly isolated IECs were washed and resuspended in
RPMI glutamax medium. To avoid endothelial and stro-
mal contamination, isolated cells were incubated with
anti-CD45, anti-CD31, anti-EpCAM, and anti-Dclk1
antibodies conjugated with the respective fluorochromes
for 30 min. The cells were washed and sorted using an
Influx-V cell sorter (Cytopeia). CD45−CD31−EpCAM
+Dclk1+ cells were collected and then subjected to
enterosphere formation assays [18, 30].
Clonogenic assay
FACs isolated Dclk1+ IECs were plated in 48-well plates
at a density of 100 cells per well in RPMI medium
containing 0.3% soft agar. The cell suspensions were
plated in a 48-well plate above a layer of solidified 1%
soft agar in plain RPMI medium. The plates were
incubated at 37 °C under 5% CO2. The cells were
followed for enterosphere/enteroid formation, as de-
scribed previously [18, 30, 31].
RNA isolation and real-time RT-PCR analysis
Total RNA isolated from small intestinal epithelial cells
was subjected to reverse transcription. The complemen-
tary DNA (cDNA) was subsequently used to perform
real-time PCR with SYBR™ chemistry (Molecular Probes,
Eugene, OR) using gene-specific primers for specific
transcripts. The crossing threshold value assessed by
real-time PCR was noted for the transcripts and normal-
ized to β-actin.
Immunoblot analysis
Twenty-five micrograms of the total protein was size-
separated in a 4–12% SDS polyacrylamide gel and
transferred electrophoretically onto a PVDF mem-
brane with a wet-blot transfer apparatus (Bio-Rad,
Hercules, CA). The membrane was blocked and in-
cubated overnight with a primary antibody and was
subsequently incubated with horseradish peroxidase-
conjugated secondary antibody. The proteins were de-
tected using ECL Western blotting detection reagents
(Amersham-Pharmacia, Piscataway, NJ). Actin (42-kD)
was used as a loading control.
Small interfering RNAs
The Dclk1 siRNA (siDclk1; Cat. # S234357) sequence
targeting the coding region of Dclk1 (accession No.
NM_019978) and scrambled siRNAs (siScr; Cat. #
AM4636) not matching any of the mouse genes were
obtained (Ambion Inc., Austin, TX, USA). DCLK siRNA
(h) (# SC45618), RELA siRNA (h) (#SC29410) and
NOTCH1 siRNA (h) (#SC36095) were obtained from
Santa Cruz Biotechnology (SCBT, TX, USA).
Synthesis and characterization of Dclk1 siRNA NPs and
treatment
Poly(lactide-co-glycolide acid nanoparticles (PLGA NPs)
were synthesized using a double emulsion solvent
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evaporation technique, as described previously [18, 20].
The amount of encapsulated siRNA was quantified using
a spectrophotometer (DU-800, Beckman Coulter, Brea,
CA). The size, polydispersity index, and zeta-potential
measurements of synthesized siRNA NPs were deter-
mined using diffraction light scattering (DLS) utilizing
Zeta PALS (Brookhaven Instruments, Holtsville, NY).
Sex- and age-matched littermates of C57BL/6 J ApcMin/+
mice were injected i.p. with 0.25 nmol of siRNA prepar-
ation on every third day for a total of six doses.
Immunohistochemistry/immunofluorescence
Standard immunohistochemistry and immunofluores-
cence protocols were used with specific antibodies, as
described previously [18, 30].
Antibodies
We used the following antibodies: Dclk1, Lgr5, Bmi1,
Hes1, Tcf4, Cox1, Cox2, EpCam, CD45, CD31 (all
from Abcam, Cambridge, MA), CXCL1, CyclinD1,
cMYC, β − catenin (Santa Cruz Biotechnology, USA),
Notch1, NfkB-p65, CyclinD1, Ras, β-actin (Cell
Signaling, Danvers, MA, USA), anti-rabbit IgG, anti-
mouse IgG, anti-goat IgG (Jackson ImmunoResearch,
West Grove, PA, USA), Alexa Fluor® 488 donkey anti-
rabbit IgG, and Alexa Fluor® 568 donkey anti-goat
IgG (Invitrogen, USA).
siRNA-mediated knockdown of DCLK1
HT-29 and DLD1 human colon cancer cells were pur-
chased from the American Type Culture Collection
(ATCC) and were maintained in DMEM medium
containing 10% fetal bovine serum (FBS). For siRNA-
mediated knockdown studies, cells were seeded into 6-
cm petri dishes and were allowed to attach overnight.
After attachment, 25 nM of commercially validated
siRNA targeting human DCLK1 or NOTCH1 or RELA
(siRNA; Santa Cruz Biotechnology) or 25 nM human
scrambled sequence (siSCR) not targeting any known
genes were complexed with Lipofectamine 3000 (Invitro-
gen) and added to the dishes in fresh cell culture
medium. After 48 h of treatment, cells were collected
for migration, invasion, colony formation, and self-
renewal (clonogenic) analysis.
Migration and invasion assay
For the invasion assay, matrigel-coated Transwells (BD
Biosciences) were prepared by retrieving in serum-free
media for 2 h at 37 °C. For the migration assay, Trans-
wells (BD Biosciences) were also used. Subsequently,
HT-29 and DLD1 cells (5000/well) pre-transfected with
either 25 nM siRNA or siSCR for 48 h were seeded into
each Transwell in triplicate in serum-free media. Cell
culture medium containing 10% FBS was added to the
bottom of each well as chemoattractant, and the cells
were incubated for 24 h at 37 °C under 5% CO2. After-
wards, a cotton swab was used to scrape non-invasive/
migratory cells off the top of Transwells; the remaining
cells were fixed with 100% methanol, stained with
0.1% crystal violet, and allowed to dry. After drying,
all invading cells were counted from each Transwell.
Results are reported as the number of cells invaded
and/or migrated.
Colony formation assay
HT-29 and DLD1 were transiently transfected with si-
DCLK1, siNFkB-p65, and si-NOTCH1 (from Santa Cruz
Biotechnology), along with scramble siRNA. After 48 h,
cells were seeded and passaged into new 6-well plates
(100 cells/well). Cells were allowed to grow for one
week, then were fixed with glacial acetic acid/methanol
solution (1:3) and washed with PBS. Colonies were
stained with 0.5% Crystal violet for 10 min and were
washed with tap water to remove excess stain. Colonies
were then counted under a stereomicroscope using a
1-cm2 grid. Four squares from four quadrants were
counted for each well.
Statistical analysis
Statistical analyses were conducted using GraphPad
Prism 6.00 (GraphPad Software, La Jolla) and R system
v3.2 for statistical computing. Pearson product–moment
correlation was used for analysis and correlation of gene
expressions between two groups. Colon cancer
recurrence-free survival analysis was performed using
Kaplan Meier Survival analyses. P values of <0.05 = *,
<0.01 = **, and 0.001 = *** were considered statistically
significant.
Results
DCLK1 is correlated with pro-survival signaling in colon
adenocarcinoma
Mutation and/or loss of function of APC is the cause of
more than 80% of colon cancers. DCLK1+ tumor stem
cells are vital to the development and progression of
colon cancer in ApcMin/+ mice models. Indeed, the
DCLK1 signature in APC mutant colon cancer predicts
recurrence-free-survival (Additional file 1: Figure S1).
Kaplan-Meier survival analysis demonstrated that the
APC-derived DCLK1 signature could be used to
strongly predict recurrence-free survival in colon can-
cer. The recurrence-free survival analysis of APC mu-
tant patients with high DCLK1 expression (n = 31)
tended to be associated with a poor prognosis com-
pared with APC mutant patients with low DCLK1
expression (n = 35; P = 0.0171).
Although the DCLK1 expression levels are important
in APC mutant colon cancer to predict the cancer
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stemness, the role of DCLK1 in regulating the prosurvi-
val signaling pathways for intestinal cancer progression
is largely unknown. Analysis of TCGA colon adenocar-
cinoma (COAD) cancer datasets demonstrated a strong
correlation between DCLK1 mRNA expression and pro-
survival signaling, including CTNNB1, NOTCH1, RELA,
PTGS1, and PTGS2, as determined by the Pearson
product–moment correlation, as previously described
(Fig. 1a). DCLK1 was most strongly correlated with
COX1 signaling in colon cancers (Additional file 2:
Figure S2). Furthermore, heatmaps demonstrating dys-
regulated expression of the pro-survival signaling signa-
ture are higher in DLCK1-high patients than in DCLK-
low patients from the TCGA COAD dataset (Fig. 1b).
The GeneMANIA webserver was utilized to predict
interactions between the DCLK1 and pro-survival sig-
naling in the network using the parameters limited to
physical interactions, genetic interactions, and pathways
to score nodes and source organism Homo sapiens as
additional parameters (Fig. 1c). From the GeneMANIA
network, it is apparent that DCLK1 has networked with
pro-survival signaling, and DCLK1 shows its interaction
with pro-survival signaling via downstream factors/
adaptor factors, exception is PTGS1 directly networking
with DCLK1. These findings suggest that DCLK1 in colon
cancers may have a relationship with pro-survival signal-
ing and, by regulating pro-survival signaling, may assist in
the development and progression of colon cancer.
ApcMin/+ mice with intestinal adenocarcinoma showed
increased expression of tumor stem cells
Tumor stem cells (TSCs) are highly tumorigenic cells
that have the ability to self-renew, giving rise to other
malignant stem cells; TSCs are also phenotypically di-
verse cancer cells that are considered to be the source of
tumor initiation and maintenance [32, 33]. To investi-
gate the role of Dclk1+ TSCs in intestinal tumorigenesis
under Apc mutation, we analyzed the level of Dclk1
Fig. 1 DCLK1 expression is positively correlated with genes of pro-survival signaling pathways and tumor stem cell markers. a Color indicates
correlation of DCLK1 and other genes: 1) negative (green), and 2) positive (red). b Heatmap of pro-survival signaling pathways and tumor stem
cell markers gene expression levels by dividing colon cancer patients into two groups based on DCLK1 expression levels from TCGA. Patients with
the top 25% or bottom 25% DCLK1 expression levels were considered DCLK1-high or DCLK1-low, respectively. c A gene network from GeneMANIA
shows the relationships for genes from the list (nodes) connected (with edges) according to the functional association networks from the databases.
Based on the physical interactions, pathway, and genetic interactions, in the network representation, all the nodes are connected and related to DCLK1
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expression and Dclk1+ cells in the intestines of ApcMin/+
and wild-type (WT) mice. Compared with WT intestinal
sections, the Dclk1 staining increased in ApcMin/+ mouse
intestines (Fig. 2a). The intensity of Dclk1 staining is 5–10
fold higher in the intestinal sections from ApcMin/+ mice
than those of WT mice (Fig. 2a and b). Furthermore,
FACS analysis of the isolated IECs of ApcMin/+ mice
showed 25-30% Dclk1+ cells compared with 1-3%
Dclk1+ cells from WT mice (Fig. 2c). We analyzed
the expression of tumor stem cell markers, and found
a massive increase in mRNA and protein levels of the
Dclk1, Lgr5, Bmi1, and Musashi1 (Fig. 2d) in the
IECs of ApcMin/+ mice compared with WT control
mice, corroborating the presence of highly tumori-
genic cells in the Apc mutant intestinal tumors. Fur-
thermore, FACS isolated Dclk1+ cells from ApcMin/+
mice were utilized for Dclk1, Lgr5 and Bmi1 mRNA
expression analysis and found that Dclk1+ cells are
enriched with the tumor stem cell markers (Additional
file 3: Figure S3).
Amplified pro-survival signaling in the IECs of ApcMin/+
mice are critical for tumorigenesis
Pro-survival signaling pathways critical for cell survival
and proliferation in IECs are required for adenoma and
adenocarcinoma formation [34–36]. In contrast to nor-
mal intestinal epithelium, neoplastic cells have active
pro-survival signaling pathways for proliferation, resist-
ance, self-renewal, and survival [37, 38]. We detected
greater expression of β-catenin, Notch, and phospho-
and total NFκB-p65 in the IECs from ApcMin/+ mice
than in IECs from WT mice. The downstream targets
COX1, COX2, CyclinD1, Tcf4, Ras, Hes-1, and CXCL1
were also upregulated in the IECs from ApcMin/+ mice
compared with IECs from WT mice (Fig. 2e and f).
Thus, Apc loss may act as a primary window for the
Fig. 2 Increased expression of Dclk1 and Dclk1+ cells in the intestinal adenomas and adenocarcinomas of ApcMin/+ mice is associated with
enhanced expression of tumor stem cell markers and pro-survival signaling. a IHC for Dclk1 in the small intestines of WT and ApcMin/+ mice.
b Staining intensity was scored and is represented as a bar graph. c FACS data representing the % Dclk1+ cells isolated from the small intestines
of WT and ApcMin/+ mice. d Differences in the number of Dclk1+ cells in staining and FACS corroborate with protein and mRNA levels of Dclk1 in
the isolated IECs of WT and ApcMin/+ mice; protein and mRNA levels analyzed by western blot and RT-PCR of Bmi1, Lgr5, and Musashi1 in isolated
IECs from WT and ApcMin/+ mice. f Protein expression levels of pro-survival signaling and their downstream targets in the isolated IECs of WT and
ApcMin/+ mice, analyzed by western blot. e mRNA expression levels of pro-survival signaling and their downstream targets in the isolated IECs of
WT and ApcMin/+ mice, analyzed by RT-PCR. All quantitative data are expressed as means ± SD of a minimum of three independent experiments.
P values of <0.05 = *, <0.01 = **, and 0.001 = *** were considered statistically significant
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dysregulation of pro-survival signaling pathways to sup-
port the transformation of IECs towards neoplasia and
promote progression. Further, these pro-survival signal-
ing pathways are required for cell and stem cell homeo-
stasis under non-neoplastic conditions; however, they
can act as oncogenic factors for tumor maintenance and
growth during neoplasia (24, 26).
Dclk1+ tumor stem cells from the intestines of ApcMin/+
mice are highly clonogenic, and the enteroids formed
display increased pro-survival signals and stemness
FACS data revealed more Dclk1+ cells from the isolated
IECs of ApcMin/+ mice than from IECs of WT controls.
Further, analysis of TCGA colon adenocarcinoma
(COAD) cancer datasets demonstrated a correlation be-
tween DCLK1 mRNA expression and tumor stem cell
markers LGR5 and BMI1, as determined by the Pearson
product–moment correlation, as previously described
(Fig. 1a). Furthermore, heatmaps demonstrating dysreg-
ulated expression of the tumor stem cell markers are
higher in DLCK1-high patients than in DCLK-low pa-
tients from the TCGA COAD dataset (Fig. 1b).
From the GeneMANIA network, it is apparent that
DCLK1 has networked with BMI1, and lacks a direct
network with LGR5 within the limited parameters of in-
teractions (Additional file 3: Figure S3). Therefore, we
investigated whether Dclk1+ tumor stem cells with the
Apc mutation have enriched co-expression of other
tumor stem cell markers, and enhanced self-renewal,
and pro-survival signaling pathways. Dclk1+ cells iso-
lated from the small intestines of ApcMin/+ mice formed
a 5-fold increase in enteroids, which were also larger
than the enteroids observed in WT mice (Fig. 3a and b).
Next, we analyzed whether Dclk1+ enteroids of ApcMin/+
mice are enriched with tumor stem cell markers and
pro-survival signaling pathways. We collected Dclk1+
enteroids and analyzed them for the expression of tumor
stem cell markers and pro-survival signaling pathways.
We found enhanced Dclk1 expression in the enteroids of
ApcMin/+ mice compared with WT mice (Fig. 3c and d).
Fig. 3 Dclk1+ cells isolated from the IECs of ApcMin/+ mice display enhanced self-renewal ability and enriched tumor stem cell markers and
pro-survival signaling. a Enteroids formation of isolated Dclk1+ cells (100 cell per well) from the small intestines of WT and ApcMin/+ mice.
b Stacked bar and line graph represent the quantification of the number of enteroids formed and spheroid volume from the Dclk1+ cells isolated
from WT and ApcMin/+ mice. c & d mRNA and protein expression of Dclk1, Bmi1, Lgr5, and Msi1 in the isolated IECs of ApcMin/+ mice compared
with WT mice. e & f mRNA and protein expression of pro-survival signaling and their downstream targets in the isolated IECs of ApcMin/+ mice
compared with WT mice. All quantitative data are expressed as means ± SD of a minimum of three independent experiments. P values
of <0.05 = *, <0.01 = **, and 0.001 = *** were considered statistically significant
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Strikingly, the expression levels of Lgr5, Bmi1, and
Musashi1 were significantly higher in the enteroids of
ApcMin/+ mice than in WT mice (Fig. 3c and d).
These data suggest that this enhancement in Dclk1
expression, along with other tumor stem cell markers,
may provide Dclk1+ cells with greater tumor stem cell
function and self-renewal ability.
We also collected the enteroids and examined the pro-
tein and gene expression of pro-survival signaling path-
ways. We found a significant increase in the expression of
β-catenin, Notch1, and the NF-κB-p65 active form (phos-
phorylation at Ser536, Ser276) and total form in the
enteroids of ApcMin/+ mice compared with WT mice
(Fig. 3e and f). Downstream targets cyclinD1, c-Myc, Tcf4,
Ras, and Hes-1 were also increased in the enteroids of
ApcMin/+ mice compared with WT. Thus, the increased
pro-survival signaling and tumor stem cell markers in the
Dclk1+ enteroids may be the source for increased self-
renewal ability and survival upon loss of Apc function.
Knocking down Dclk1 expression decreased the intestinal
tumorigenesis in ApcMin/+ mice
Dclk1 expression levels and Dclk1-expressing cells are en-
hanced in the IECs of ApcMin/+ mice. These findings sug-
gest that Dclk1 may play a crucial role in development and
progression of intestinal tumors under the loss of Apc
function. To test our hypothesis that Dclk1 is required for
intestinal tumorigenesis under the loss of Apc function, we
inhibited Dclk1 gene expression using siDclk1-NPs, along
with si-Scramble-Nanoparticles (siScr-NPs) as a control, in
ApcMin/+ and WT mice. Histological observations of intes-
tinal sections revealed fewer polyps and reduced dysplasia
in the intestines of ApcMin/+ mice treated with siDclk1-
NPs compared with siScr-NPs (Additional file 4: Figure
S4). Compared with siScr-NPs treatment, siDclk1-NPs
treatment reduced the intensity of Dclk1 staining (~3fold)
in intestinal sections from ApcMin/+ mice (Fig. 4a). Further-
more, FACS analysis of Dclk1+ cells from the isolated IECs
of ApcMin/+ mice showed that siDclk1-NPs treatment sig-
nificantly reduced the number of Dclk1+ cells compared
with siScr-NPs treatment (Fig. 4b). Significantly lower ex-
pression of Dclk1 and the other tumor stem cell markers,
Lgr5, Bmi1, and Musashi1, were detected in the isolated
IECs of siDclk1-NP–treated ApcMin/+ mice (Fig. 4c and d).
However, expression of Bmi1 and Msi1 was either un-
changed or increased in the siDclk1-NP–treated WT mice
(Fig. 4c and d). No change in crypt architecture or abnor-
malities was observed in the WT mice treated with
siDclk1-NPs or siScr-NPs as previously reported [18].
Dclk1 regulates pro-survival signaling pathways to
support intestinal tumorigenesis in ApcMin/+ mice
Conserved pro-survival signaling pathways, most notably
the β-catenin, Notch, and NFkB pathways, coordinately
regulate tumor formation and progression [34–36]. In
the present study, we found that Dclk1+ cells isolated
from the intestinal epithelium of ApcMin/+ mice display
enhanced expression of pro-survival signaling pathways
and self-renewal ability (Fig. 3). To test whether Dclk1
regulates pro-survival signaling pathways in the isolated
IECs from ApcMin/+ mice, we silenced Dclk1 expression
using siDclk1-NPs. Depleting Dclk1 in ApcMin/+ mice
had a potent inhibitory effect on the pro-survival β-
catenin, Notch1, and NF-κB-p65 signaling pathways in
the isolated IECs (Fig. 4e and f). To further clarify
whether the inhibitory activity of β-catenin, Notch1, and
NF-κB-p65 signaling caused by Dclk1 depletion is con-
nected with an associated change in target gene expres-
sion, downstream targets COX1, COX2, CyclinD1, Tcf4,
Ras, Hes-1, and Cxcl1 were quantified and were ob-
served to be reduced in the IECs from ApcMin/+ mice
treated with si-Dclk1-NP (Fig. 4e and f).
These data suggest that the Dclk1 expression level is
indispensable for the activation of pro-survival signaling
pathways upon loss of Apc function. However, the ex-
pression of pro-survival signaling was not altered in the
IECs of WT mice treated with si-Dclk1-NP, except for a
marginal increase in CyclinD1, suggesting that cell
cycling may be controlled by Dclk1 expression levels
(Fig. 4e and f ). Together, knocking down Dclk1
decreased the pro-survival signaling in the IECs of
ApcMin/+ mice but not significantly in the WT mice.
Dclk1 is required for intestinal tumorigenesis in ApcMin/+
mice
Stemness and self-renewal ability are the key features in
tumorigenesis, for tumor initiation and progression [33].
To determine whether Dclk1 is critical for intestinal
tumorigenesis, we inhibited Dclk1 gene expression using
siDclk1-NPs, along with siScr-NPs as control, in ApcMin/+
mice. The self-renewal ability of Dclk1+ cells and their
clonal populations is reduced with siDclk1-NP treatment,
as evidenced by fewer and smaller enteroids formed from
Dclk1+ cells of ApcMin/+ mice (Fig. 5a-c). Next, we ana-
lyzed whether Dclk1+ enteroids of ApcMin/+ mice treated
with siDclk1-NP displayed diminished tumor stem cell
markers and pro-survival signaling pathways. We found
reduced Dclk1 expression in the enteroids of ApcMin/+
mice treated with siDclk1-NP compared with siScr-NPs
(Fig. 5d). Expression levels of Lgr5, Bmi1, and Musashi1
were also significantly reduced in the enteroids of ApcMin/
+ mice treated with siDclk1-NP (Fig. 5d).
In addition, we examined the protein and gene expres-
sion of pro-survival signaling pathways and found that
the expression of β-catenin, Notch1, and the NF-κB-p65
active form (phosphorylation at Ser536, Ser276) and
total form in the enteroids of Apc(Min/+) mice treated
with siDclk1-NP was less than the expression in mice
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treated with siScr-NP (Fig. 5e). Downstream targets
cyclinD1, c-Myc, Tcf4, Ras, and Hes-1 were also reduced
in the enteroids of Apc(Min/+) mice treated with siDclk1-
NP (Fig. 5e). Together, these data suggest that Dclk1 is
important and required for i) intestinal tumorigenesis, ii)
increased stemness during neoplasia, and iii) increased
pro-survival signaling to support tumor progression. To-
gether, the present data suggests that Dclk1 knockdown
downregulates pro-survival signaling, stemness, polyps,
and, thus, tumorigenesis.
Silencing the pro-survival signaling Notch1 and RELA in
human colon cancer cell lines reduced cancer cells’ self-
renewal and progression
To further investigate whether DCLK1 regulates APC
mutant colon tumorigenesis via pro-survival signaling
pathways, we knocked down NOTCH1 and RELA in
colon cancer cell lines and monitored for self-renewal
and colony formation ability and migration and invasion
in vitro. We utilized siRNAs against NOTCH1 and NF-
κB-p65 (RELA) to deplete their gene expression in
DLD1 and HT29 colon cancer cells. We also used siR-
NAs against DCLK1 in the colon cancer cells as a pro-
portional strategy. Protein and mRNA expression
analysis confirmed a significant decrease in NOTCH1,
RELA, and DCLK1 protein and mRNA levels in cancer
cells treated with the respective siRNAs (Fig. 6a). The ef-
fect of NOTCH1 and RELA knockdown on the self-
renewal ability of DLD1 and HT29 cells was analyzed
with a clonogenic assay. We found that the number of
colonospheres formed was significantly reduced with
siRNA treatment against NOTCH1 and RELA5 com-
pared with the si-Scramble treatment (Fig. 6b). Indeed,
DCLK1 knockdown showed higher inhibitory action on
Fig. 4 Dclk1 knockdown reduced the expression of Dclk1 and Dclk1+ cells and the associated expression of tumor stem cell markers and
pro-survival signaling in the ApcMin/+ mice. a IHC for Dclk1 in the small intestines of ApcMin/+ mice treated with siDclk1-NPs and siScramble-NPs;
staining intensity was scored and represented as a bar graph. b FACS data representing the % Dclk1+ cells isolated from the small intestines of
ApcMin/+ mice treated with siDclk1-NPs compared with siScramble-NPs. c & d mRNA and protein expression levels of Dclk1, Bmi1, Lgr5, and
Musashi1 in the isolated IECs of WT and ApcMin/+ mice treated with siDclk1-NPs and siScramble-NPs, analyzed by RT-PCR and western blot.
f Protein expression levels of pro-survival signaling and their downstream targets in the isolated IECs of WT and ApcMin/+ mice, analyzed by western
blot. e mRNA expression levels of pro-survival signaling and their downstream targets in the isolated IECs of WT and ApcMin/+ mice, analyzed by
RT-PCR. All quantitative data are expressed as means ± SD of a minimum of three independent experiments. P values of <0.05 = *, <0.01 = **, and
0.001 = *** were considered statistically significant
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colon cancer cell self-renewal ability than NOTCH1 or
RELA inhibition (Fig. 6b). Colon cancer cells’ colony-
forming ability, which represents the cells’ viability and
survival, was reduced in cells treated with siRNAs
against NOTCH1 and RELA (Fig. 7a). Like colony for-
mation, colon cancer cells’ in vitro migration and inva-
sion were significantly reduced with siRNA treatment
against Notch1 and NF-κB-p65, compared with si-
Scramble treatment (Fig. 7b and c). However, the inhibi-
tory effect of siNOTCH1 and siRELA on colon cancer
cell colony formation and invasion/migration was less
than the effect of siDCLK1 treatments (Fig. 7b and c).
DCLK1 knockdown in colon cancer cells also reduced
the mRNA expression levels of NOTCH1, RELA and
ERK1/2 (Additional file 5: Figure S5). Finally to test the
effect of MAPK inhibition in the regulation of BMI1 ex-
pression in the colon cancer cells, ERK1/2 siRNA was
treated to the cells and found that their inhibition
decreased the expression of BMI1 (Additional file 6:
Figure S6). The present data suggest that pro-surivial
signaling may support the colon cancer cell self-renewal
and progression. Together, these results revealed that
DCLK1 controls the pro-survival signaling pathways in
colon cancer cells to support the survival and stemness
of tumor cells vital for their progression.
Discussion
Our previous studies demonstrated that Dclk1 overex-
pression is correlated with intestinal cancer progression
and that silencing Dclk1 decreased the number and size
of polyps, adenoma, and adenocarcinoma, suggesting
that Dclk1 plays an important active role in intestinal
tumorigenesis [18, 28, 39, 40]. Tumor cell self-renewal
and survival ability are the key features in tumorigenesis,
for tumor progression [33]. Pro-survival signaling path-
ways, most notably the ß-catenin, Notch, and NFkB
Fig. 5 Dclk1 knockdown in the Apcmin/+ mice reduced the stemness and pro-survival signaling of Dclk1+ cells. a Enteroids formation of isolated
Dclk1+ cells (100 cell per well) from the small intestines of ApcMin/+ mice treated with siDclk1-NPs and siScramble-NPs. b Stacked bar and c line
graph represent the quantification of the number of enteroids formed and spheroid volume from the isolated Dclk1+ cells of ApcMin/+ mice.
d mRNA and protein expression of Dclk1, Bmi1, Lgr5, and Msi1 in the isolated IECs of ApcMin/+ mice treated with siDclk1-NPs and siScramble-NPs.
e & f mRNA and protein expression of pro-survival signaling and their downstream targets in the isolated IECs of ApcMin/+ mice treated with
siDclk1-NPs and siScramble-NPs. All quantitative data are expressed as means ± SD of a minimum of three independent experiments. P values
of <0.05 = *, <0.01 = **, and 0.001 = *** were considered statistically significant
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pathways, coordinately regulate tumor cell survival and
self-renewal [34–36]. However, whether Dclk1 regulates
intestinal tumor cell survival and self-renewal for
tumorigenesis through pro-survival signaling pathways is
largely unknown. In the present study, we used ApcMin/+
mice, an excellent model to evaluate human FAP and
sporadic colorectal cancer [1, 2, 7]. Consistent with our
previous studies, we found increased expression of Dclk1
in the IECs of ApcMin/+ mice, which exhibit high-grade
dysplasia and adenocarcinoma [12, 18, 20]. It has been
suggested that stem-like cells or stem cells are more
abundant in cancerous conditions, and that the loss of
Apc function increases the expansion of the tumor stem
cell (TSC) compartment [3, 41]. Loss of Apc function
significantly increased the expression of tumor stem cell
markers Dclk1, Lgr5, Bmi1, and Musashi in the IECs.
However, how loss of Apc selects the cell type or stem
cell type in the process of tumorigenesis is yet to be
identified. Apc regulates the Wnt signaling, which is crit-
ical for the maintenance of Lgr5+ stem cells and initi-
ation and progression of cancer [3]. It is recently
reported that Lgr5+ stem cells give rise to Dclk1+ cells in
the intestinal epithelium [13]. Therefore, we suggest that
the loss of Apc may induce the specific expansion of
Lgr5+ cells derived Dclk1+ cells for intestinal tumori-
genesis. However, the expansion of other stem cells
and the specific expansion of Dclk1+ cells need to be
investigated in future. We also observed enhanced
self-renewal ability of Dclk1+ cells isolated from the
intestines of ApcMin/+ mice.
Cellular pro-survival signaling pathways are intercon-
nected, complex signaling networks, and their upregula-
tion is well illustrated in cancers [42]. The aberrant
upregulation or constitutive activation of multiple
survival-signaling pathways in cancer cells promotes
proliferation and stemness, inhibits apoptosis, and in-
creases survival and the ability to invade and migrate
into surrounding tissues and metastasize to distant sites
[42, 43]. We found here that the ß-catenin, Notch, and
NFkB pro-survival signaling pathways are upregulated in
the isolated IECs of ApcMin/+ mice. We further deter-
mined that Dclk1+ cells of ApcMin/+ mice display en-
hanced pro-survival signaling pathways, compared with
Dclk1− cells. These findings suggest that the enhanced
Fig. 6 Silencing DCLK1 and pro-survival signaling NOTCH1 and RELA reduce the self-renewal ability of human colon cancer cells (DLD1 & HT29).
a Protein and mRNA expression levels of DCLK1, NOTCH1, and RELA in the DLD1 and HT29 colon cancer cells transfected with si-DCLK1,
si-NOTCH1, and siRELA compared with siScramble-transfected cells. b Self-renewal ability of DLD1 and HT29 cells after the knockdown of DCLK1,
NOTCH1, and RELA; bar graph represents the average number of spheroids formed from DLD1 and HT29 cells after the knockdown of DCLK1,
NOTCH1, and RELA. All quantitative data are expressed as means ± SD of a minimum of three independent experiments. P values of <0.05 were
considered statistically significant
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pro-survival signaling pathways could be a vital factor
for tumor progression by regulating tumor stem cells
and/or tumor cell stemness. Several studies have indi-
cated that Dclk1 promotes the multistep process of can-
cer formation and progression [13, 18, 31, 40, 44–46]. It
has been suggested that Dclk1 can regulate pluripotency
factors, miRNAs, and signaling pathways, including
NOTCH and Runx2, in cancer and non-cancer cells
[46–48]. In the present study, we witnessed a similar
phenomenon; the pro-survival signaling pathways were
upregulated in the IECs of ApcMin/+ mice, in which
Dclk1 expression is higher than in controls. We ob-
served that silencing Dclk1 reduced the pro-survival sig-
naling pathways in the IECs of ApcMin/+ mice. We have
previously demonstrated that downregulation of DCLK1
can up-regulate critical miRNAs in both in vitro and in
vivo cancer models and resulted in decreased pro-
survival signaling and EMT-related transcription factors
[13, 20, 44, 47]. Indeed, the enterospheres formed from
the isolated Dclk1+ cells of ApcMin/+ mice treated with
si-Dclk1-NPs display reduced pro-survival signaling
pathways, which may be the reason for reduced self-
renewal and tumor stem cells.
We further investigated the connection between pro-
survival signaling pathways and Dclk1 expression in the
ApcMin/+ mice with high-grade dysplasia and intramuco-
sal adenocarcinoma. We observed that inhibition of
NOTCH and RELA reduced the colon cancer cell lines
DLD1 and HT29 self-renewal ability, survival/viability,
and invasion/migration in vitro. However, DCLK1
knockdown is highly effective at inhibiting the self-
renewal, colony formation, and invasion/migration of
colon cancer cells than the NOTCH or RELA inhibition
in vitro. Furthermore, DCLK1 knockdown decreased the
expression of NOTCH, RELA and MAPK in colon can-
cer cells, suggesting that DCLK1 may act as a master
Fig. 7 Silencing DCLK1 and pro-survival signaling reduced the survival ability of human DLD1 & HT29 colon cancer cells. a Colony formation
ability of DLD1 and HT29 cells after the knockdown of DCLK1, NOTCH1, and RELA; bar graph represents the average number of colonies formed
from DLD1 and HT29 cells after the knockdown of DCLK1, NOTCH1, and RELA. b In vitro invasion and migration of DLD1 cells after the knockdown of
DCLK1, NOTCH1, and RELA; bar graph represents the number of cells migrated and invaded after the knockdown of DCLK1, NOTCH1, and RELA. c In
vitro invasion and migration of HT29 cells after the knockdown of DCLK1, NOTCH1, and RELA, bar graph represents the number of cells migrated and
invaded after the knockdown of DCLK1, NOTCH1, and RELA. All quantitative data are expressed as means ± SD of a minimum of three independent
experiments. P values of <0.05 were considered statistically significant
Chandrakesan et al. Molecular Cancer  (2017) 16:30 Page 12 of 14
regulator for multiple pro-survival signaling pathways,
which could explain why any individual knockdown of
pro-survival signaling is less effective than DCLK1
knockdown in inhibiting cancer cells’ self-renewal and
progression. Our findings suggest that Dclk1 can regu-
late multiple signaling pathways for cancer formation
and progression. However, the exact regulation mechan-
ism of Dclk1 requires further clarification.
Conclusions
In conclusion, we found that Dclk1 was enhanced in
Apc mutant intestinal tumors, and elevated tumor stem-
ness and survival by regulating the pro-survival signaling
pathways. We also determined that Dclk1 knockdown
reduced tumor stemness, polyps, adenoma, and adeno-
carcinoma by inhibiting pro-survival signaling and sup-
pressing their downstream oncogenes. Together, these
results suggest that Dclk1, a tumor stem cell marker,
may be a potential therapeutic target for colon cancer
therapy.
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